Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2023-04-04 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 142.2KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and provides details about share issuance without disclosure under part 6D.2 of the Corporations Act. The document is short (1434 characters) and is a formal regulatory notice about share issuance rather than a full financial report or detailed announcement. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-04-04 English
Notification of cessation of securities - TLX 5 pages 26.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of various securities such as options, share rights, and share appreciation rights due to conditions not being met. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. There is no indication of financial results, management discussion, or regulatory certifications. The document is an official announcement regarding changes in the company's issued securities, specifically the cessation of certain securities. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities status changes and does not fit into more specific categories like capital changes (SHA) which typically involve new issues or splits rather than cessation/lapse notifications. The document length and detail also support it being a full announcement rather than a brief notice or report publication announcement.
2023-04-04 English
Notification of upcoming quarterly results and investor call 2 pages 126.0KB
Report Publication Announcement Classification · 95% confidence The document is an ASX release announcing the upcoming release of Telix Pharmaceuticals Limited's Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023. It also notifies about an investor conference call/webcast scheduled after the report release. The document does not contain the actual financial data or the report itself but rather informs about the timing and details of the report release and related investor event. The document length is 5472 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2023-04-04 English
Illuccix European Marketing Authorisation Application Update 2 pages 131.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing the filing of a Marketing Authorisation Application (MAA) for a pharmaceutical product. It provides updates on regulatory filings and marketing authorisation progress but does not contain financial statements, detailed financial performance data, or management analysis. The document is relatively short (6465 characters) and serves as a corporate announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about marketing authorisation applications and related corporate updates that do not fit other specific categories.
2023-04-02 English
Non-Executive Director Leave of Absence 1 page 113.
Board/Management Information Classification · 100% confidence The document is an ASX release announcing that a Non-Executive Director, Dr Andreas Kluge, has been granted a leave of absence for approximately six months. It provides background information about the director and the company but does not contain financial data, report content, or voting results. The document is a management or board-related announcement about a change in the board's status rather than a full report or financial disclosure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (2504 characters), and it is not an announcement of a report publication or a certification, so other categories like RPA or RNS do not apply.
2023-03-28 English
Application for quotation of securities - TLX 7 pages 31.1KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including numbers, issue dates, and whether the securities are cash consideration or not. The document is focused on the issuance and quotation of new shares resulting from exercised options and convertible securities. There is no financial performance data, management discussion, or regulatory certification. The content aligns with announcements related to share issues or capital changes rather than a full financial report or other categories. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (8375 characters) and detailed issuance data support this classification with high confidence.
2023-03-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.